Paul Averback, MD, DABP, President and CEO, Chairman of the Board
Dr. Paul Averback is the founder, CEO and President of Nymox. Dr. Averback has extensive firsthand knowledge of health care, including as an emergency room physician, family physician, clinic administrator and university Medical Faculty member. In addition to many issued and pending patents, Dr. Averback has published prolifically in the scientific and medical literature on subjects such as Alzheimer's disease, pharmaceuticals, neuropathology, neuroanatomy, diagnostics, vascular disease, oncology, cytology, congenital disease, embryology, geometrical probability and morphometry. Dr. Averback holds a Diploma of the American Board of Pathology with Special Competence in Neuropathology, was a Medical Research Council Postdoctoral Fellow at Cambridge University, England, and was on the Faculty of Medicine at McGill University.
Randall Lanham, Independent Director
Randall Lanham is an Orange County attorney with extensive experience in securities law and corporate finances. Mr. Lanham has vast experience in both domestic and international corporate legal matters.
Paul F. McDonald, Independent Director
Paul F. McDonald, a graduate in law of McGill University, has been Vice-President of the Montreal Exchange, principal owner and president of a stock-exchange firm, and a longtime director of the Quebec Industrial Development Corporation, and brings a lifetime of experience as a member of the investment industry to the Nymox board.
Professor David Morse, Independent Director
Professor David Morse, Ph.D. is a Professor at the University of Montreal and a world expert in the biochemistry, proteomics and genomics of cell function. Professor Morse has published extensively in the peer-reviewed scientific literature, including papers in journals such as Science, Nature, Cell, Proceedings of the National Academy of Science, and the Journal of Biological Chemistry.